Effect of buckminsterfullerenes on cells of the innate and adaptive immune system: An in vitro study with human peripheral blood mononuclear cells

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4571-4580

  Bunz, Hanno ^a   Plankenhorn, Sandra ^a   Klein, Reinhild ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Buckminsterfullerenes; Cytokines; Dendritic cells; N ethyl polyamino C60; Natural killer cells; Polyhydroxy C60; T cells

Indexed keywords

BCG VACCINE; CD56 ANTIGEN; CD69 ANTIGEN; CELL MARKER; CYTOKINE; FULLERENE; FULLERENE DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOTOXIN; N ETHYL POLYAMINO C 60; POLYHYDROXY C 60; TETANUS TOXOID; THYMIDINE; TUBERCULIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ADULT; ANTIGENS; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FEMALE; FULLERENES; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; MALE; STATISTICS, NONPARAMETRIC;

MYCOBACTERIUM BOVIS BCG;

EID: 84870345506     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33773     Document Type: Article

References (50)

1. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: Buckminsterfullerene. Nature. 1985;318:162-163.
2. Kroto HW, Allaf AW, Balm SP. C60: buckminsterfullerene. Chem Rev. 1991;91:1213-1235.
3. Lee VS, Nimmanpipug P, Aruksakunwong O, Promsri S, Sompornpisut P, Hannongbua S. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations. J Mol Graph Model. 2007;26(2):558-570.
4. Bakry R, Vallant RM, Najam-ul-Haq M, etal. Medicinal applications of fullerenes. Int J Nanomedicine. 2007;2(4):639-649.
5. Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003;38(11-12):913-923.
6. Lee J, Mahendra S, Alvarez PJ. Nanomaterials in the construction industry: a review of their applications and environmental healthy and safety considerations. ACS Nano. 2010;4(7):3580-3590.
7. Mashino T, Shimotohno K, Ikegami N, etal. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett. 2005;15(4):1107-1109.
8. Bosi S, Da Ros T, Castellano S, Banfi E, Prato M. Antimycobacterial activity of ionic fullerene derivatives. Bioorg Med Chem Lett. 2000; 10(10):1043-4045.
9. Friedman SH, DeCamp DL, Sijbesma RP, Srdanov G, Wudl F, Kenyon GL. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J Am Chem Soc. 1993;115(15):6506-6509.
10. Durdagi S, Mavromoustakos T, Chronakis N, Papadopoulos MG. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations. Bioorg Med Chem. 2008;16(23):9957-9974.
11. Ibrahim M, Saleh NA, Hameed AJ, Elshemey WM, Elsayed AA. Structural and electronic properties of new fullerene derivatives and their possible application as HIV-1 protease inhibitors. Spectrochim Acta A Mol Biomol Spectrosc. 2010;75(2):702-709.
12. Nielsen GD, Roursgaard M, Jensen KA, Poulsen SS, Larsen ST. In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol. 2008;103(3):197-208.
13. Kolosnjaj J, Szwarc H, Moussa F. Toxicity studies of fullerenes and derivatives. Adv Exp Med Biol. 2007;620:168-180.
14. Yamawaki H, Iwai N. Cytotoxicity of water-soluble fullerene in vascular endothelial cells. Am J Physiol Cell Physiol. 2006;290(6):C1495-C1502.
15. Isakovic A, Markovic Z, Todorovic-Markovic B, etal. Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. Toxicol Sci. 2006;91(1):173-183.
16. Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials. 2005;26(36):7587-7595.
17. Liu Y, Jiao F, Qiu Y, etal. Immunostimulatory properties and enhanced TNF-α mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology. 2009;14;20(41):415102.
18. Montanez MI, Ruiz-Sanchez AJ, Perez-Inestrosa E. A perspective of nanotechnology in hypersensitivity reactions including drug allergy. Curr Opin Allergy Clin Immunol. 2010;10(4):297-302.
19. Yang D, Zhao Y, Guo H, etal. [Gd@C82(OH)22]n nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano. 2010;4(2):1178-1186.
20. Zhu J, Ji Z, Wang J, etal. Tumor-inhibitory effect and immunomodulatory activity of fullerol C60(OH)x. Small. 2008;4(8):1168-1175.
21. Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology. 2006;225(1):48-54.
22. Yudoh K, Karasawa R, Masuko K, Kato T. Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. Int J Nanomedicine. 2009;4:217-225.
23. Porter AE, Gass M, Muller K, Skepper JN, Midgley P, Welland M. Visualizing the uptake of C60 to the cytoplasm and nucleus of human monocyte-derived macrophage cells using energy-filtered transmission electron microscopy and electron tomography. Environ Sci Technol. 2007;41(8):3012-3017.
24. Calvaresi M, Zerbetto F. Baiting proteins with C60. ACS Nano. 2010;4(4):2283-2299.
25. Barth H, Klein K, Börtlein A, etal. Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced Th1, relapsing-remitting course with enhanced T H0 reactivity. J Neuroimmunol. 2002;133(1-2):175-183.
26. Barth H, Berg PA, Klein R. Methods for the in vitro determination of an individual disposition towards TH1-or TH2-reactivity by the application of appropriate stimulatory antigens. Clin Exp Immunol. 2003;134(1):78-85.
27. Thaher F, Plankenhorn S, Klein R. Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro. Int Immunopharmacol. 2011;11(11):1724-1731.
28. Barth H, Klein R, Berg PA, Wiedenmann B, Hopf U, Berg T. Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection. Hepatogastroenterology. 2003;50(49):201-206.
29. Klein R, Buck S, Classen K, Rostock M, Huber R. Enhanced in vitro activation of immunocompetent cells in healthy individuals being subcutaneously 'vaccinated' with placebo (physiological saline). Clin Immunol. 2008;126(3):322-331.
30. Klein R, Schwenk M, Heinrich-Ramm R, Templeton DM. Diagnostic relevance of the lymphocyte transformation test for sensitization to beryllium and other metals. Pure Appl Chem. 2004;76(6):1269-1281.
31. Klein R, Schwenk M, Templeton DM. Cytokine profiles in human exposure to metals (IUPAC Technical Report). Pure Appl Chem. 2006;78(11):2155-2168.
32. Klein R. Evidence for immunological (allergic) mechanisms in a subgroup of patients with phenprocoumon-induced liver disease. Eur J Clin Pharmacol. 2009;65(12):1195-1201.
33. Brattig NW, Diao GJ, Berg PA. The specificity of the lymphocyte transformation test in a patient with hypersensitivity reactions to pyrazolone compounds. A 10-week follow-up study before and after rechallence. Eur J Clin Pharmacol. 1988;35(1):39-45.
34. Ryan JJ, Bateman HR, Stover A, etal. Fullerene nanomaterials inhibit the allergic response. J Immunol. 2007;179(1):665-672.
35. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1(6):510-514.
36. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
37. Dellinger A, Zhou Z, Lenk R, MacFarland D, Kepley CL. Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation. Exp Dermatol. 2009;18(12):1079-1081.
38. Dellinger A, Zhou Z, Norton SK, Lenk R, Conrad D, Kepley CL. Uptake and distribution of fullerenes in human mast cells. Nanomedicine. 2010;6(4):575-582.
39. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Translat Med. 2011;9:216.
40. Frick JS, Zahir N, Muller M, etal. Colitogenic and non-colitogenic commensal bacteria differentially trigger DC maturation and Th cell polarization: an important role for IL-6. Eur J Immunol. 2006;36(6):1537-1547.
41. Hedge S, Pahne J, Smola-Hess S. Novel immunosuppressive properties of interleukin-6in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. FASEB J. 2004;18(12):1439-1441.
42. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun. 2011;3(3):258-263.
43. Andersen AJ, Hashemi SH, Andresen TL, Hunter AC, Moghini SM. Complement: alive and kicking nanomedicines. J Biomed Nanotechnol. 2009;5(4):364-372.
44. Fusakio ME, Mohammed JP, Laumonnier Y, Hoebe K, Köhl J, Mattner J. C5a regulates NKT and NK cell functions in sepsis. J Immunol. 2011;187:5805-5812.
45. Qing X, Koo GC, Salmon JE. Complement regulates conventional DC-mediated NK-cell activation by inducing TGF-b1in Gr-1 (+) myeloid cells. Eur J Immunol. April 25, 2012. [Epub ahead of print.]
46. Mikawa M, Kato H, Okunura M, etal. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjugate Chem. 2001;12(4):510-514.
47. Liu Y, Jiao F, Qiu Y, etal. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. Biomaterials. 2009;30(23-24):3934-3945.
48. Dumortier H, Lacotte S, Pastorin G, etal. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006;6(7):1522-1528.
49. Bianco A, Hobeke J, Godefroy S, etal. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J Am Chem Soc. 2005;127(1):58-59.
50. Ali SS, Hardt JI, Quick KL, etal. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radical Biol Med. 2004;37(8):1191-1202.